Skip to main content

Bausch Health Companies Inc. (BHC) Stock Analysis

HoldModerate Confidence

Healthcare · Drug Manufacturers - Specialty & Generic

Hold if already holding. Not a fresh buy at $5.32, but acceptable to hold if already in. Reasons: Concentration risk — Product: Xifaxan (85.0%); Concentration risk — Product: Arestin (95.0%).

Bausch Health is a global specialty pharma and medical device company with ~$10.3B in 2025 revenues across five segments: Salix (GI/GI drugs), Bausch+Lomb (~88% owned eye health subsidiary), International, Solta Medical (aesthetics), and Diversified. Products are sold in ~90... Read more

$5.32+23.9% A.UpsideScore 6.3/10#4 of 29 Drug Manufacturers - Specialty & Generic
QualityF-score8 / 9FCF yield56.33%
Stop $5.09Target $6.59(analyst − 13%)A.R:R 2.5:1
Analyst target$7.57+42.3%7 analysts
$6.59our TP
$5.32price
$7.57mean
$9

Hold if already holding. Not a fresh buy at $5.32, but acceptable to hold if already in. Reasons: Concentration risk — Product: Xifaxan (85.0%); Concentration risk — Product: Arestin (95.0%). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Maintain position. Not compelling to add more. Score 6.3/10, moderate confidence.

Passes 7/9 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 71d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: aggressive.

Val9.1Qual5.8Grw7.7Mom2.5Sent5.8Ins5.0Peer5.5Tech6.4Risk6.26.3OVERALL

Recent Developments — Bausch Health Companies Inc.

Latest news

Generated 2026-05-20T21:06:21Z.

Thesis

Rewards
Sector modifier (Healthcare): +0.5
Strong earnings beat streak (3/4)
Attractive valuation
Risks
Concentration risk — Product: Xifaxan (85.0%)
Concentration risk — Product: Arestin (95.0%)
Negative news sentiment (-0.67)

Key Metrics

P/E (TTM)—
P/E (Fwd)1.3
Mkt Cap$2.0B
EV/EBITDA6.2
Profit Mgn-11.5%
ROE—
Rev Growth11.7%
Beta0.42
DividendNone
Rating analysts9

Quality Signals

Piotroski F8/9MoatNarrow

Options Flow

P/C0.66bullish
IV67%elevated

Concentration Risks(10-K Item 1A)

  • HIGHProductXifaxan85%
    10-K Item 1: 'Sales of the Xifaxan® product line currently represent approximately 85% of the Salix segment revenues'
  • HIGHProductArestin95%
    10-K Item 1: 'Arestin® is indicated as an adjunct to scaling and root planing...represents approximately 95% of Dentistry revenues'

Material Events(8-K, last 90d)

  • 2026-03-02Item 5.02LOW
    Bausch Health amended 2023 performance share unit awards for CEO Thomas Appio (1,137,862 PSUs) and EVP Seana Carson (137,922 PSUs) to settle in cash at market price on the March 3, 2026 vesting date, rather than stock. No reason cited for the change in settlement method.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

1 floor-breaker·1 ceiling hit

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Obv
1.0
Ma Position
1.0
Volume
3.0
Macd
3.2
Rsi
4.5
Volume distribution (falling OBV)Below 200-MA, MA slope -2.1%/30d — confirmed downtrend
GatesMomentum 2.5<4.5Death cross (50MA < 200MA)A.R:R 2.5 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 71d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARSuitability: Aggressive
RSI
40 · Neutral
↓ 20D MA↓ 50D MA↓ 200D MADEATH CROSSSupport $5.25Resistance $6.29

Price Targets

$5
$7
A.Upside+23.9%
A.R:R2.5:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeRisk-Off

Risk Alerts

! Momentum score 2.5/10 — below 4.5 minimum
! Death cross — 50-day MA below 200-day MA

Earnings

B
B
B
M
3/4 beats
Next Earnings2026-07-29 (71d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is BHC stock a buy right now?

Hold if already holding. Not a fresh buy at $5.32, but acceptable to hold if already in. Reasons: Concentration risk — Product: Xifaxan (85.0%); Concentration risk — Product: Arestin (95.0%). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Maintain position. Not compelling to add more. Target $6.59 (+23.9%), stop $5.09 (−4.5%), A.R:R 2.5:1. Score 6.3/10, moderate confidence.

What is the BHC stock price target?

Take-profit target: $6.59 (+23.9% upside). Target $6.59 (+23.9%), stop $5.09 (−4.5%), A.R:R 2.5:1. Stop-loss: $5.09.

What are the risks of investing in BHC?

Concentration risk — Product: Xifaxan (85.0%); Concentration risk — Product: Arestin (95.0%); Negative news sentiment (-0.67).

Is BHC overvalued or undervalued?

Bausch Health Companies Inc. trades at a P/E of N/A (forward 1.3). TrendMatrix value score: 9.1/10. Verdict: Hold.

What do analysts say about BHC?

9 analysts cover BHC with a consensus score of 2.4/5. Average price target: $8.

What does Bausch Health Companies Inc. do?Bausch Health is a global specialty pharma and medical device company with ~$10.3B in 2025 revenues across five...

Bausch Health is a global specialty pharma and medical device company with ~$10.3B in 2025 revenues across five segments: Salix (GI/GI drugs), Bausch+Lomb (~88% owned eye health subsidiary), International, Solta Medical (aesthetics), and Diversified. Products are sold in ~90 countries; the company plans to separate its Bausch+Lomb eye health business.

Related stocks: NBIX (Neurocrine Biosciences, Inc.) · INDV (Indivior Pharmaceuticals, Inc.) · ANIP (ANI Pharmaceuticals, Inc.) · COLL (Collegium Pharmaceutical, Inc.) · LNTH (Lantheus Holdings, Inc.)